24/7 Market News Snapshot 03 February, 2025 – Invivyd, Inc. Common Stock (NASDAQ:IVVD)

February 3, 2025

DENVER, Colo., 03 February, 2025 (247marketnews.com) – (NASDAQ:IVVD) are discussed in this article.
Invivyd, Inc. (IVVD) is experiencing noteworthy activity in the market, with its stock price soaring to $0.434 in premarket trading, reflecting an impressive increase of over 21.33% from the previous closing of $0.358. The trading volume reached 8.05 million shares, underscoring significant investor interest and sentiment towards the company. Such price movement indicates a potential breakout from previous resistance levels, suggesting a favorable outlook for IVVD as it continues to attract attention from traders and investors alike.

In conjunction with this financial momentum, Invivyd recently announced the successful recruitment and administration of all doses in its Phase 1/2 clinical trial for VYD2311, a novel monoclonal antibody designed to enhance protection and treatment of COVID-19. This trial, involving 40 participants, explores multiple routes of administration and aims to position VYD2311 as a superior alternative to existing vaccines with its promising safety profile and enhanced efficacy.

Initial data from the trial indicate that VYD2311 exhibits a strong average neutralization potency—approximately 17 times greater against current SARS-CoV-2 variants compared to existing treatments. The drug’s safety profile has been favorable, with reported adverse events categorized as mild to moderate and largely unrelated to the study drug. Notably, serum concentrations at Day 65 reflect sustained high levels, suggesting the potential for less frequent dosing.

Marc Elia, Chairman of Invivyd, expressed optimism about VYD2311’s potential to transform COVID-19 management, particularly for immunocompromised individuals. Meanwhile, Tim Lee, Chief Commercial Officer, emphasized the urgent need for effective treatment options in the context of ongoing COVID-19 challenges. The company remains dedicated to working with regulatory authorities to ensure timely access to its innovative therapeutic solution for those most at risk.

Related news for (IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.